This product(s) resides on a APICMO contract.
The ability to produce, synthesize and manufacture large quantities of Pyrrolo[2,3-d]pyrimidin-4-ol (3680-71-5) with quality control system under CGMP manufacturing
APICMO offers a wide range of products which includes Pyrrolo[2,3-d]pyrimidin-4-ol. It belongs to intermediates category. Contact us for more information.
This product(s) resides on a APICMO contract. If you are viewing this page as a non-registered user, the price(s) displayed is List Price. To view your pricing, log in using your account number, or become a registered user by contacting one of our Customer Service teams. To place an order, contact APICMO Customer Service.
Pyrrolo[2,3-d]pyrimidin-4-ol (3680-71-5) Specifications
|CAS Min %||98%|
|CAS Max %||100%|
|Chemical Name or Material||Pyrrolo[2,3-d]pyrimidin-4-ol|
|Molecular Weight (g/mol)||135.12|
Pyrrolo[2,3-d]pyrimidin-4-ol (3680-71-5) Safety and Handling
(3680-71-5) Hazard description:
♦ Causes serious eye irritation.
♦ May cause an allergic skin reaction.
Pyrrolo[2,3-d]pyrimidin-4-ol (3680-71-5) Precautionary statement:
♦ Avoid breathing dust/fume/gas/mist/vapors/spray.
♦ Wear protective gloves/protective clothing/eye protection/face protection.
♦ IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
♦ IF SKIN irritation or rash occurs: Get medical advice/attention.
Wash contaminated clothing before reuse.
WARNING: The information provided on this web site was developed in compliance with European Union (EU) regulations and is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guide for safe handling and use. It is not to be considered as either a warranty or quality specification.
Pyrrolo[2,3-d]pyrimidin-4-ol (3680-71-5) Articles
FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients.
Adverse drug reactions (ADRs) reduce patients’ quality of life, increase mortality and morbidity, and have a negative economic impact on healthcare systems.
Hematological Oncology 2018
Therapeutic Strategies for Leukodystrophic Disorders Resulting from Perinatal Asphyxia: Focus on Myelinating Oligodendrocytes.
Perinatal asphyxia results from the action of different risk factors like complications during pregnancy, preterm delivery, or long and difficult labor.
Molecular Neurobiology 2018
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Pyrrolo[2,3-d]pyrimidin-4-ol (3680-71-5) Bulk Ordering & Pricing:
Need larger quantities for your development, manufacturing or research applications?